Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier

J. F. Poduslo, G. L. Curran

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Much research is now focused on a potential vaccine for Alzheimer's disease (AD). Current studies involve administering the amyloid β peptide (Aβ) in Freund's complete adjuvant, which cannot be used in humans. Our studies show that the immune complex of Aβ is taken up by a receptor-mediated process at the blood - brain barrier (BBB). The success of immunization for AD, therefore, may be critically dependent on circulating Aβ levels which are lower in AD patients compared to AD transgenic mice. Moreover, we have found that modifying the antibody with polyamine increases its BBB permeability and may provide a better approach to passive immunization for Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)3197-3200
Number of pages4
JournalNeuroReport
Volume12
Issue number15
StatePublished - Oct 29 2001

Fingerprint

Blood-Brain Barrier
Amyloid
Alzheimer Disease
Vaccines
Peptides
Passive Immunization
Freund's Adjuvant
Polyamines
Antigen-Antibody Complex
Transgenic Mice
Immunization
Permeability
Antibodies
Research

Keywords

  • Alzheimer's disease
  • Amyloid β peptide
  • Blood-brain barrier
  • Immune complex
  • Passive immunization
  • Permeability coefficient-surface

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. / Poduslo, J. F.; Curran, G. L.

In: NeuroReport, Vol. 12, No. 15, 29.10.2001, p. 3197-3200.

Research output: Contribution to journalArticle

@article{844a9621cfe2415c9afbd01e9fb88579,
title = "Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier",
abstract = "Much research is now focused on a potential vaccine for Alzheimer's disease (AD). Current studies involve administering the amyloid β peptide (Aβ) in Freund's complete adjuvant, which cannot be used in humans. Our studies show that the immune complex of Aβ is taken up by a receptor-mediated process at the blood - brain barrier (BBB). The success of immunization for AD, therefore, may be critically dependent on circulating Aβ levels which are lower in AD patients compared to AD transgenic mice. Moreover, we have found that modifying the antibody with polyamine increases its BBB permeability and may provide a better approach to passive immunization for Alzheimer's disease.",
keywords = "Alzheimer's disease, Amyloid β peptide, Blood-brain barrier, Immune complex, Passive immunization, Permeability coefficient-surface",
author = "Poduslo, {J. F.} and Curran, {G. L.}",
year = "2001",
month = "10",
day = "29",
language = "English (US)",
volume = "12",
pages = "3197--3200",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier

AU - Poduslo, J. F.

AU - Curran, G. L.

PY - 2001/10/29

Y1 - 2001/10/29

N2 - Much research is now focused on a potential vaccine for Alzheimer's disease (AD). Current studies involve administering the amyloid β peptide (Aβ) in Freund's complete adjuvant, which cannot be used in humans. Our studies show that the immune complex of Aβ is taken up by a receptor-mediated process at the blood - brain barrier (BBB). The success of immunization for AD, therefore, may be critically dependent on circulating Aβ levels which are lower in AD patients compared to AD transgenic mice. Moreover, we have found that modifying the antibody with polyamine increases its BBB permeability and may provide a better approach to passive immunization for Alzheimer's disease.

AB - Much research is now focused on a potential vaccine for Alzheimer's disease (AD). Current studies involve administering the amyloid β peptide (Aβ) in Freund's complete adjuvant, which cannot be used in humans. Our studies show that the immune complex of Aβ is taken up by a receptor-mediated process at the blood - brain barrier (BBB). The success of immunization for AD, therefore, may be critically dependent on circulating Aβ levels which are lower in AD patients compared to AD transgenic mice. Moreover, we have found that modifying the antibody with polyamine increases its BBB permeability and may provide a better approach to passive immunization for Alzheimer's disease.

KW - Alzheimer's disease

KW - Amyloid β peptide

KW - Blood-brain barrier

KW - Immune complex

KW - Passive immunization

KW - Permeability coefficient-surface

UR - http://www.scopus.com/inward/record.url?scp=0035968932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035968932&partnerID=8YFLogxK

M3 - Article

C2 - 11711855

AN - SCOPUS:0035968932

VL - 12

SP - 3197

EP - 3200

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 15

ER -